Literature DB >> 29168014

Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy.

Daisuke Tezuka1,2,3, Hisanori Kosuge4, Masahiro Terashima5, Nozomu Koyama6,4, Tadashi Kishida6, Yuko Tada7, Jun-Ichi Suzuki8, Tetsuo Sasano9,10, Takashi Ashikaga11, Kenzo Hirao9, Mitsuaki Isobe11.   

Abstract

Late gadolinium enhancement (LGE) with cardiac magnetic resonance (CMR) imaging has demonstrated the capability of stratifying hypertrophic cardiomyopathy (HCM). Stress perfusion test of CMR can quantify myocardial perfusion reserve (MPR), but its clinical role is not determined. The purpose of this study was to investigate the relationship between MPR and LGE in patients with HCM. A total of 61 consecutive cases underwent complete evaluation with electrocardiography and CMR [cine imaging, coronary MR angiography (MRA), and stress perfusion testing with LGE]. HCM cases were diagnosed by the Japanese conventional guideline prior to this CMR study. Mild LVH was defined as more than 13 mm in maximum LV wall thickness at end diastole on the cine imaging of the CMR. MPR was calculated as the ratio of stress/rest myocardial blood flow using an intensity curve on the stress perfusion test. Cases with ischemic heart disease were excluded from the study based on clinical history and coronary MRA. There were 37 HCM and 24 mild LVH cases (average age: 60.5 ± 10.9 vs. 64.8 ± 10.8; male: 62.2 vs. 75.0%, respectively, non-significant). MPR in HCM was lower than in LVH (1.5 ± 0.5 vs. 2.2 ± 0.9, p < 0.001) and normal subjects (2.4 ± 0.9, p < 0.001). MPR in HCM with LGE (N = 34) was lower than in HCM without LGE (N = 3) (1.4 ± 0.5 vs. 2.1 ± 0.2, p = 0.014). Multiple regression analysis verified that LGE was the strongest predictor of MPR among multiple clinical parameters, including LVH, LV dysfunction (ejection fraction < 50%), and the presence of negative T wave (p < 0.001). MPR was impaired in HCM with LGE compared with HCM without LGE. The clinical role of MPR on CMR needs to be clarified by further research.

Entities:  

Keywords:  Cardiac magnetic resonance imaging (CMR imaging); Hypertrophic cardiomyopathy (HCM); Myocardial perfusion reserve (MPR)

Mesh:

Substances:

Year:  2017        PMID: 29168014     DOI: 10.1007/s00380-017-1088-y

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  32 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012) - Digest Version .

Authors: 
Journal:  Circ J       Date:  2016-02-03       Impact factor: 2.993

3.  Evaluation of cardiac magnetic resonance imaging parameters to detect anatomically and hemodynamically significant coronary artery disease.

Authors:  Hideki Futamatsu; Norbert Wilke; Chris Klassen; Steven Shoemaker; Dominick J Angiolillo; Alan Siuciak; Kino Morikawa-Futamatsu; Nobuaki Suzuki; Franz von Ziegler; Theodore A Bass; Marco A Costa
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

4.  Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Evan Appelbaum; Caitlin J Harrigan; Jacki Buros; C Michael Gibson; Connie Hanna; John R Lesser; James E Udelson; Warren J Manning; Barry J Maron
Journal:  Circ Heart Fail       Date:  2008-06-23       Impact factor: 8.790

5.  Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy.

Authors:  Paco E Bravo; Stefan L Zimmerman; Hong-Chang Luo; Iraklis Pozios; Mahadevan Rajaram; Aurélio Pinheiro; Charles Steenbergen; Ihab R Kamel; Richard L Wahl; David A Bluemke; Frank M Bengel; M Roselle Abraham; Theodore P Abraham
Journal:  Circ Cardiovasc Imaging       Date:  2013-02-15       Impact factor: 7.792

6.  Quantification of MRI measured myocardial perfusion reserve in healthy humans: a comparison with positron emission tomography.

Authors:  Thomas Fritz-Hansen; Jens D Hove; Klaus F Kofoed; Henning Kelbaek; Henrik B W Larsson
Journal:  J Magn Reson Imaging       Date:  2008-04       Impact factor: 4.813

7.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; S E Epstein; W C Roberts
Journal:  J Am Coll Cardiol       Date:  1986-09       Impact factor: 24.094

8.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

Review 9.  Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Martin S Maron
Journal:  J Cardiovasc Magn Reson       Date:  2012-02-01       Impact factor: 5.364

10.  Regional Stress-Induced Ischemia in Non-fibrotic Hypertrophied Myocardium in Young HCM Patients.

Authors:  Robert Jablonowski; Eva Fernlund; Anthony H Aletras; Henrik Engblom; Einar Heiberg; Petru Liuba; Håkan Arheden; Marcus Carlsson
Journal:  Pediatr Cardiol       Date:  2015-06-12       Impact factor: 1.655

View more
  5 in total

Review 1.  Advances in MRI Applications to Diagnose and Manage Cardiomyopathies.

Authors:  Ramya Vajapey; Brendan Eck; Wilson Tang; Deborah H Kwon
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-27

Review 2.  Cardiovascular magnetic resonance imaging for structural heart disease.

Authors:  Yiling Situ; Samuel C M Birch; Camila Moreyra; Cameron J Holloway
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

Review 3.  The Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Hypertrophic Cardiomyopathy.

Authors:  Sanjay Sivalokanathan
Journal:  Diagnostics (Basel)       Date:  2022-01-26

4.  Pathogenic variant of RBM20 in a multiplex family with hypertrophic cardiomyopathy.

Authors:  Natsuko Inagaki; Takeharu Hayashi; Yasuyoshi Takei; Hisanori Kosuge; Shinji Suzuki; Kousuke Tanimoto; Taishiro Chikamori; Akinori Kimura
Journal:  Hum Genome Var       Date:  2022-02-18

5.  Inline perfusion mapping provides insights into the disease mechanism in hypertrophic cardiomyopathy.

Authors:  Claudia Camaioni; Kristopher D Knott; Joao B Augusto; Andreas Seraphim; Stefania Rosmini; Fabrizio Ricci; Redha Boubertakh; Hui Xue; Rebecca Hughes; Gaby Captur; Luis Rocha Lopes; Louise Anne Elizabeth Brown; Charlotte Manisty; Steffen Erhard Petersen; Sven Plein; Peter Kellman; Saidi A Mohiddin; James C Moon
Journal:  Heart       Date:  2019-12-10       Impact factor: 5.994

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.